Pharmacists Now Able to Prescribe Paxlovid
July 6, 2022Comirnaty Receives Full FDA Approval for Expanded Age Group
July 8, 2022July 6, 2022 – Mylan Pharmaceuticals has recalled one batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3mL prefilled pens. The product is packaged in cartons of five pens and is being recalled due to the potential for missing labels on some pens.
- There is no impact to members through Benecard Central Fill.
- Insulin glargine is indicated to improve glycemic control in adults who have type 1 or type 2 diabetes and pediatric patients who have type 1 diabetes. A missing label on insulin glargine pens could lead to a mix-up of products/strengths if a patient uses more than one type of insulin. This could cause potentially dangerous high or low blood sugar. As of the recall date, Mylan had received no reports of related adverse events.
- Mylan advises patients to contact Sedgwick at 1-877-643-8438 for the documentation packet to return the product if they have unlabeled insulin glargine pens. Questions regarding this recall can be directed to Viatris Customer Relations at 1-800-796-9526 or customer.service@viatris.com. Mylan recommends patients contact a healthcare provider if they have experienced any problems that may be related to using the recalled product.
- Full recall details are available on the U.S. FDA’s website.